Will it be 2023 despite the whole year in which synthetic intelligence will be in the prime time of biopharmacy?That’s the prediction, along with one more list, released today via Syneos Health in its annual trend report.
Technology and knowledge feature prominently in their prediction with AI, virtual transformations, local market adoption, the expansion of “age technology,” and an overall redesign of the virtual effect on fitness and fitness care decisions.
Unlock this story right away and sign up for over 153,900 biopharmaceutical professionals to read endpoints daily, and it’s free.
Since squandering a questionable orphan drug exclusivity court case last year, the FDA’s Office of Orphan Product Development has remained completely silent on the orphan exclusivity of any approved product since last November, leaving many sponsors on what to expect.
This silence means that for more than 70 indications designated as orphans for more than 60 products, UNRWA has made a public ruling on seven-year-old orphan exclusivity in the Orange Book, and no new orphan exclusivity lists appear in UNRWA’s search database, as recently noted through George O’Brien, spouse in the Washington office of Mayer Brown. DIRECT CURRENT.
Talking about treatment didn’t cause Lily to suffer from attention deficit hyperactivity disorder or ADHD. But a video game did.
As the 10-year-old soars above icy waters and points to flying creatures on the snowy planet Frigidus, she develops her attention skills, thanks to Akili Interactive Labs’ video game EndeavorRx. She is now less worried and scattered, allowing her to continue taking a low dose of ADHD medication, according to her mother, Violet Vu.
Unlock this article and others by subscribing to one of our paid plans.
Researchers still have key questions about Eisai’s investigational Alzheimer’s drug, lecanemab, after more phase III knowledge was published in the New England Journal of Medicine late Tuesday.
In the paper, which was published alongside presentations at an Alzheimer’s conference, the trial researchers write that a definition of clinical significance “has not been established. “It has left experts calling for more: the status quo of a prospective confrontation to exactly outline the extent of the difference the drug makes in patients’ lives.
Unlock this article and others by subscribing to one of our paid plans.
Ahead of the FDA’s ruling on Eli Lilly’s Alzheimer’s drug donanemab in February, the big drug company is releasing the first component of information from one of the most attractive, though less regulatory, trials at an Alzheimer’s convention in San Francisco.
In the blind study of 148 people, Eli Lilly pitted his drug against Aduhelm, Biogen’s drug that won FDA approval but lost Medicare policy outside of clinical trials. amyloid, a protein whose accumulation is linked to Alzheimer’s disease, in the brain.
Unlock this story right away and sign up for over 153,900 biopharmaceutical professionals to read endpoints daily, and it’s free.
ViiV Healthcare is assembling an eclectic coalition of client companies in a new White House-approved effort to end HIV by the end of the decade.
The new action of the US industryto end HIV includes pharmaceutical and fitness companies (Gilead Sciences, CVS Health and Walgreens), but extends to a wide range of client companies, including Tinder, Uber and Walmart.
ViiV is the catalyst for the group, investing over a million dollars in seed cash and serving as master of ceremonies for today’s launch on World AIDS Day, however, co-creator Health Action Alliance will organize registration activities in the future. ViiV and the alliance needs and expects more corporations to not only sign up for the effort, but also for funding.
Unlock this story right away and sign up for over 153,900 biopharmaceutical professionals to read endpoints daily, and it’s free.
Pharmaceutical advertisers on Twitter are over, at least for now. Ad spending among previous big spenders fell last week, according to the most recent knowledge of ad tracker Pathmatics, amid continued turbulence after billionaire boss Elon Musk took over a month ago.
Of the 18 most sensible advertisers tracked by Endpoints News, only two spend: GSK and Bayer. GSK’s spending for the entire week to Sunday’s low was just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier, expanding spending to $499,000 last week from $480,000 the week before. Bayer’s spending also marks a sharp buildup from a month ago and before Musk’s purchase, when he was spending $16,000 a week.
Unlock this article and others by subscribing to one of our paid plans.
Before Roche turns all eyes to a new edition of its gantenerumab, an Alzheimer’s drug that has failed more than once, Big Pharma had to deepen knowledge about November’s failure at a more annual convention than in previous years thanks to closely watched rivals. . in the field: Eisai and Biogen’s lecanemab and Eli Lilly’s donanemab.
There was a difference of less than 10 percent between Roche’s drug and placebo to slow cognitive decline in two phase III trials, involving only about 2,000 Alzheimer’s patients. In its presentation at Wednesday’s conference, Roche said it had noticed fewer scans of venomous proteins anticipated. For years, researchers and investors have poured their resources into the concept that greater amyloid clearance would equate to reduced cognitive decline.
Unlock this story right away and sign up for over 153,900 biopharmaceutical professionals to read endpoints daily, and it’s free.
After 24 years without confirmation of clinical benefit, the FDA announced Tuesday morning that Viatris (formed through Pfizer’s Mylan and Upjohn) made the decision to recall a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said it was not imaginable to conduct a confirmatory study.
Sulfamylon first gained accelerated FDA approval in 1998 as a topical burn treatment, and the FDA noted that last December, Mylan told the company it was not completing the trial.
Unlock this story right away and sign up for over 153,900 biopharmaceutical professionals to read endpoints daily, and it’s free.
Gilead won a victory last week in its ongoing patent with the CDC on the HIV drug Truvada for pre-exposure prophylaxis (PrEP).
The U. S. Federal Court of Claims The U. S. Supreme Court ruled on Nov. 21 that the government violated certain agreements with Gilead by failing to immediately notify the company about its patent programs for Truvada for PrEP, according to documents unsealed Wednesday.
The challenge dates back to approximately 2004, when Truvada won accelerated approval to treat HIV. Because HIV is known to increase resistance to treatment, patients at that time had to take more than one medication at a time. Truvada combines Gilead’s older HIV drugs. medications, Emtriva and Viread, making life less difficult for patients who used to take separate pills daily. Soon after, the CDC and Gilead partnered to study the use of Truvada as a preventive measure before exposure.
© Endpoints Company 2022
We will email you a link to set a new password. Please note that this link is for single use and is valid for 24 hours.